EP3853172A1 - Methods for preparing arylphosphine-borane complexes - Google Patents

Methods for preparing arylphosphine-borane complexes

Info

Publication number
EP3853172A1
EP3853172A1 EP19779698.0A EP19779698A EP3853172A1 EP 3853172 A1 EP3853172 A1 EP 3853172A1 EP 19779698 A EP19779698 A EP 19779698A EP 3853172 A1 EP3853172 A1 EP 3853172A1
Authority
EP
European Patent Office
Prior art keywords
hours
solvent
vol
aryldihalophosphine
nabh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19779698.0A
Other languages
German (de)
French (fr)
Other versions
EP3853172B1 (en
Inventor
Siyu TU
Jessica L. KLINKENBERG
Yiyong He
Xiaoyun Chen
Haoquan Li
Matthew S. REMY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Global Technologies LLC
Original Assignee
Dow Global Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies LLC filed Critical Dow Global Technologies LLC
Publication of EP3853172A1 publication Critical patent/EP3853172A1/en
Application granted granted Critical
Publication of EP3853172B1 publication Critical patent/EP3853172B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B6/00—Hydrides of metals including fully or partially hydrided metals, alloys or intermetallic compounds ; Compounds containing at least one metal-hydrogen bond, e.g. (GeH3)2S, SiH GeH; Monoborane or diborane; Addition complexes thereof
    • C01B6/06—Hydrides of aluminium, gallium, indium, thallium, germanium, tin, lead, arsenic, antimony, bismuth or polonium; Monoborane; Diborane; Addition complexes thereof
    • C01B6/10—Monoborane; Diborane; Addition complexes thereof
    • C01B6/13—Addition complexes of monoborane or diborane, e.g. with phosphine, arsine or hydrazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/505—Preparation; Separation; Purification; Stabilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5045—Complexes or chelates of phosphines with metallic compounds or metals

Definitions

  • the present specification generally relates to methods for preparing borane complexes from aryldihalophosphines.
  • the present specification is directed to methods for preparing borane complexes from aryldihalophosphines with a solution comprising sodium borohydride.
  • Arylphosphines have potential uses as raw materials to commercial ligands in transition metal catalysis.
  • phosphines are prone to oxidation and/or combustion, which make them dangerous to transport and handle.
  • intermediary complexes of arylphosphines are formed that are less dangerous to transport and handle.
  • the intermediary complexes can either be used in place of arylphosphines, or the intermediary complexes can be converted back to arylphosphines when they have safely been transported and/or handled.
  • Intermediary complexes of arylphosphines that have been particularly useful are borane complexes of arylphosphines.
  • methods for preparing phosphine-borane complexes from aryldihalophosphine comprise: mixing sodium borohydride (NaBH 4 ), a solvent comprising at least 50 volume percent (vol%) glycol ethers, and the aryldihalophosphine to obtain a solution; and maintaining the solution at a reaction temperature for a duration of time to obtain the phosphine-borane complexes.
  • the glycol ethers comprises l,2-dimethoxyethane
  • the solvent further comprises tetrahydrofuran.
  • a ratio of tetrahydrofuran to l,2-dimethoxyethane in the solvent comprising may be from 0.1: 1.0 to 2.5: 1.0. In some embodiments, a ratio of sodium borohydride to aryldihalophosphine is from 1.1:1.0 to 2.5:l.O.
  • FIG. 1 is a 1H NMR spectrum and peak assignments for a 2,4- dimethoxyphenylphosphine-borane complex according to embodiments disclosed and described herein;
  • FIG. 2 is a 13 C NMR spectrum and peak assignments for a 2,4- dimethoxyphenylphosphine-borane complex according to embodiments disclosed and described herein;
  • FIG. 3 is a 31 P NMR spectrum for 2,4-dimethoxyphenylphosphine-borane complex (upper spectrum), 2,4-dimethoxyphenyl-P,P-dichlorophosphine (lower spectrum), and 2,4- dimethoxyphenylpho spine (inset) according to embodiments disclosed and described herein; and
  • FIG. 4 is a 31 P NMR spectrum for phenylphosphine-borane complex according to the embodiments disclosed and described herein.
  • BH THF borane tetrahydrofuran complex
  • BH 3 -SMe 2 borane dimethyl sulfide
  • NaBH 4 sodium borohydride
  • DME l,2-dimethoxyethane
  • THF tetrahydrofuran
  • CDC1 3 deuterated chloroform
  • ZnCl 2 zinc chloride
  • s seconds
  • ppm parts per million
  • Hz hertz
  • psec microseconds
  • mm millimeter
  • g gram
  • mmol millimolar
  • mL milliliter.
  • Aryl phosphine borane complexes are generally prepared in two steps: (1) reduction of an aryldichlorophosphine to a phosphine; and (2) subsequent reaction with a borane source such as borane tetrahydrofuran complex (BH 3 THF) or borane dimethyl sulfide (BH 3 SMe 2 ).
  • a borane source such as borane tetrahydrofuran complex (BH 3 THF) or borane dimethyl sulfide (BH 3 SMe 2 ).
  • BH 3 THF borane tetrahydrofuran complex
  • BH 3 SMe 2 borane dimethyl sulfide
  • Another preparation route that has been considered and is used to form borane complexes with some phosphines include using sodium borohydride (NaBH 4 ).
  • methods for preparing phosphine-borane complexes from aryldihalophosphine comprise: mixing sodium borohydride (NaBH 4 ), a solvent comprising at least 50 vol% glycol ethers, and the aryldihalophosphine to obtain a solution; and maintaining the solution at a reaction temperature for a duration of time to obtain the phosphine-borane complexes.
  • NaBH 4 sodium borohydride
  • solvent comprising at least 50 vol% glycol ethers
  • methods for preparing phosphine-borane complexes from aryldihalophosphine comprises mixing NaBH 4 and the aryldihalophosphine in a solvent comprising 50 vol% glycol ethers.
  • the NaBH 4 used in methods for preparing phosphine-borane complexes is not limited and can be commercially available NaBH 4 .
  • the NaBH 4 is powdered NaBH 4 with a purity greater than 98%, such as greater than 99%.
  • the aryldihalophosphine that is mixed with NaBH 4 to form an arylphosphine-borane complex may be, in embodiments, an aryldichlorophosphine, such as, for example, an aryldichlorophosphine selected from the group consisting of dichloro(2,4- dimethoxyphenyl)phosphine, dichloro(2-methoxyphenyl)phosphine, and dichlorophenylphosphine.
  • the aryldihalophosphine may be a mono-aryldihalophosphine, such as, for example, mono-aryldichlorophosphine.
  • THF is a solvent that is commonly used to form phosphine- borane complexes.
  • THF is used as the sole solvent for preparing phosphine- borane complexes.
  • a solvent comprising THF alone will not produce a phosphine-borane complex with NaBH 4 and aryldihalophosphine, such as, for example, aryldichlorophosphine. The solution to this issue is not readily ascertainable.
  • Lam, Hubert et al., Mild Reduction of Chlorophosphine Boranes to Secondary Phosphine Boranes, 44 Tetrahedron Letters, 5213-5216 (2003) discloses that a preformed chlorophosphine-borane complex, generated by mixing the chloropho spine and BH 3» THF, produced a phosphine-borane complex by mixing NaBH 4 and diary lmonohalophosphine-borane complex in a solvent that only comprises THF ( i.e solvent is 100 vol% THF).
  • NaBH 4 and aryldihalophosphine will not form a phosphine-borane complex in a solvent that only comprises THF.
  • a phosphine-borane complex is prepared by mixing NaBH 4 and aryldihalophosphine in a solvent.
  • a desired phosphine-borane complex may be formed by mixing NaBH 4 and aryldihalophosphine at an appropriate ratio.
  • a ratio of NaBH 4 to aryldichlorophosphine is from 1.1: 1.0 to 2.5: 1.0, such as from 1.2: 1.0 to 2.5: 1.0, from 1.3: 1.0 to 2.5: 1.0, from 1.4: 1.0 to 2.5: 1.0, from 1.5: 1.0 to 2.5: 1.0, from 1.6: 1.0 to 2.5: 1.0, from 1.7: 1.0 to 2.5:1.0, from 1.8:1.0 to 2.5:1.0, from 1.9:1.0 to 2.5:1.0, from 2.0:1.0 to 2.5:1.0, from 2.1:1.0 to 2.5: 1.0, from 2.2: 1.0 to 2.5: 1.0, from 2.3: 1.0 to 2.5: 1.0, or from 2.4: 1.0 to 2.5: 1.0.
  • a ratio of NaBH 4 to aryldichlorophosphine is from 1.1: 1.0 to 2.4: 1.0, such as from 1.1:1.0 to 2.3:1.0, from 1.1:1.0 to 2.2:1.0, from 1.1:1.0 to 2.1:1.0, from 1.1:1.0 to 2.0:1.0, from 1.1:1.0 to 1.9:1.0, from 1.1:1.0 to 1.8:1.0, from 1.1:1.0 to 1.7:1.0, from 1.1:1.0 to 1.6:1.0, from 1.1:1.0 to 1.5:1.0, from 1.1:1.0 to 1.4:1.0, from 1.1:1.0 to 1.3:1.0, or from 1.1:1.0 to 1.2:1.0.
  • a ratio of NaBH 4 to aryldichlorophosphine is from 1.2: 1.0 to 2.4: 1.0, such as from 1.3: 1.0 to 2.3: 1.0, from 1.4: 1.0 to 2.2: 1.0, from 1.5: 1.0 to 2.1:1.0, from 1.6: 1.0 to 2.0: 1.0, or from 1.7: 1.0 to 1.9: 1.0.
  • a ratio of NaBH 4 to aryldichlorophosphine is from 1.5:1.0 to 2.2:1.0, such as from 1.6:1.0 to 2.1:1.0, from 1.7:1.0 to 2.0:1.0, or from 1.8:1.0 to 1.9:1.0.
  • Methods for preparing phosphine-borane complexes from aryldihalophosphine comprises mixing NaBH 4 and aryldihalophosphine in a solvent comprising at least 50 vol% glycol ethers, such as at least 55 vol% glycol ethers, at least 60 vol% glycol ethers, at least 65 vol% glycol ethers, at least 70 vol% glycol ethers, at least 75 vol% glycol ethers, at least 80 vol% glycol ethers, at least 85 vol% glycol ethers, at least 90 vol% glycol ethers, or at least 95 vol% glycol ethers.
  • a solvent comprising at least 50 vol% glycol ethers, such as at least 55 vol% glycol ethers, at least 60 vol% glycol ethers, at least 65 vol% glycol ethers, at least 70 vol% glycol ethers, at least 75 vol% glycol ethers, at least 80 vol% glycol ethers, at least 85
  • the glycol ethers in the solvent may comprise 1,2- dimethoxyethane (DME), triglyme, diglyme, or mixtures thereof.
  • the glycol ethers in the solvent comprise DME.
  • the solvent in which NaBH 4 and aryldihalophosphine is mixed may comprise at least 50 vol% DME, such as at least 55 vol% DME, at least 60 vol% DME, at least 65 vol% DME, at least 70 vol% DME, at least 75 vol% DME, at least 80 vol% DME, at least 85 vol% DME, at least 90 vol% DME, or at least 95 vol% DME.
  • the solvent in which NaBH 4 and aryldihalophosphine are mixed may, in embodiments, comprise components other than glycol ethers. According to some embodiments, the solvent in which NaBH 4 and aryldihalophosphine are mixed may comprise tetrahydrofuran (THF), toluene, or mixtures thereof.
  • THF tetrahydrofuran
  • the solvent may comprise from 5 vol% to 50 vol% THF, such as from 10 vol% to 50 vol% THF, from 15 vol% to 50 vol% THF, from 20 vol% to 50 vol% THF, from 25 vol% to 50 vol% THF, from 30 vol% to 50 vol% THF, from 35 vol% to 50 vol% THF, from 40 vol% to 50 vol% THF, or from 45 vol% to 50 vol% THF.
  • THF such as from 10 vol% to 50 vol% THF, from 15 vol% to 50 vol% THF, from 20 vol% to 50 vol% THF, from 25 vol% to 50 vol% THF, from 30 vol% to 50 vol% THF, from 35 vol% to 50 vol% THF, from 40 vol% to 50 vol% THF, or from 45 vol% to 50 vol% THF.
  • the solvent may comprise from 5 vol% to 45 vol% THF, such as from 5 vol% to 40 vol% THF, from 5 vol% to 35 vol% THF, from 5 vol% to 30 vol% THF, from 5 vol% to 25 vol% THF, from 5 vol% to 20 vol% THF, from 5 vol% to 15 vol% THF, or from 5 vol% to 10 vol% THF.
  • the solvent may comprise from 10 vol% to 45 vol% THF, such as from 15 vol% to 40 vol% THF, from 20 vol% to 35 vol% THF, or from 25 vol% to 30 vol% THF.
  • the solvent in which NaBH 4 and aryldihalophosphine are mixed may comprise a mixture of DME and THF.
  • the solvent in which NaBH 4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.1: 1.0 to 2.5: 1.0, such as from 0.2: 1.0 to 2.5: 1.0, from 0.3: 1.0 to 2.5: 1.0, from 0.4: 1.0 to 2.5: 1.0, from 0.5:1.0 to 2.5:1.0, from 0.6:1.0 to 2.5:1.0, from 0.7:1.0 to 2.5:1.0, from 0.8:1.0 to 2.5:1.0, from
  • the solvent in which NaBH 4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.1: 1.0 to 2.4: 1.0, such as from 0.1: 1.0 to 2.3: 1.0, from 0.1: 1.0 to 2.2: 1.0, from 0.1: 1.0 to 2.2: 1.0, from 0.1: 1.0 to 2.1:1.0, from 0.1: 1.0 to 2.0: 1.0, from 0.1: 1.0 to
  • the solvent in which NaBH 4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.2: 1.0 to 2.4: 1.0, such as from 0.3: 1.0 to 2.3: 1.0, from 0.4: 1.0 to 2.2: 1.0, from 0.5: 1.0 to 2.1:1.0, from 0.6: 1.0 to
  • the solvent in which NaBH 4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.1: 1.0 to 1.0:1.0, such as from 0.2:1.0 to 0.9:1.0, from 0.3:1.0 to 0.8:1.0, from 0.4:l.0 to 0.7:1.0, or from 0.5:1.0 to 0.7:1.0.
  • NaBH 4 and aryldihalophosphine may be mixed by adding each as a dry component to a solvent that comprises at least 50 vol% glycol ethers.
  • NaBH 4 may be added to a first solvent to form a first suspension
  • aryldihalophosphine may be added to a second solvent to form a second suspension.
  • the first suspension and the second suspension are combined, which results in mixing the NaBH 4 and aryldihalophosphine.
  • the first solvent and the second solvent may be the same or different.
  • each of the first solvent and the second solvent may comprise at least 50 vol% glycol ethers so that when the first suspension and the second suspension are combined, the combined solvent comprises at least 50 vol% glycol ethers.
  • the composition of the first solvent and the composition of the second solvent should be formulated such that when the first suspension and the second suspension are combined, the combined solvent comprises at least 50 vol% glycol ethers. It should be understood that a skilled artisan is capable of formulating the first solvent and the second solvent so that when the first suspension and the second suspension are combined, the combined solvent comprises at least 50 vol% glycol ethers.
  • At least one of the first solvent and/or the second solvent comprises at least 50 vol% glycol ethers.
  • at least one of the first solvent and/or the second solvent may comprise THF.
  • the first solvent and the second solvent may be formulated to yield the THF to DME ratios disclosed herein.
  • embodiments of methods for preparing phosphine borane complexes disclosed and described herein comprise mixing NaBH 4 and aryldihalophosphine in a solvent comprising at least 50 vol% glycol ethers to obtain a solution, and maintaining the solution at a reaction temperature.
  • the reaction temperature may be from 0 °C to 60 °C, such as from 5 °C to 60 °C, from 10 °C to 60 °C, from 15 °C to 60 °C, from 20 °C to 60 °C, from 25 °C to 60 °C, from 30 °C to 60 °C, from 35 °C to 60 °C, from 40 °C to 60 °C, from 45 °C to 60 °C, from 50 °C to 60 °C, or from 55 °C to 60 °C.
  • the reaction temperature may be from 0 °C to 55 °C, such as from 0 °C to 50 °C, from 0 °C to 45 °C, from 0 °C to 40 °C, from 0 °C to 35 °C, from 0 °C to 30 °C, from 0 °C to 25 °C, from 0 °C to 20 °C, from 0 °C to 15 °C, from 0 °C to 10 °C, or from 0 °C to 5 °C.
  • the reaction temperature may be from 5 °C to 55 °C, such as from 10 °C to 50 °C, from 15 °C to 45 °C, from 20 °C to 40 °C, or from 20 °C to 35 °C.
  • the solvent may be adjusted to the reaction temperature before NaBH 4 and/or aryldihalophosphine is added to the solvent.
  • NaBH 4 and/or aryldihalophosphine may be added to the solvent at ambient temperature and the mixture of NaBH 4 , aryldihalophosphine, and solvent are adjusted to the reaction temperature.
  • NaBH 4 is added to a first solvent to form a first suspension and aryldihalophosphine is added to a second solvent to form a second suspension
  • the first solvent and/or the second solvent may be adjusted to the reaction temperature before the NaBH 4 and/or aryldihalophosphine is added to the first solvent and/or second solvent, respectively.
  • NaBH 4 is added to a first solvent at ambient temperature to form a first suspension and/or aryldihalophosphine is added to a second solvent at ambient temperature to form a second suspension, and the first suspension and/or the second suspension may be adjusted to the reaction temperature after the NaBH 4 and/or aryldihalophosphine is added to the first solvent and/or second solvent, respectively.
  • NaBH 4 is added to a first solvent at ambient temperature to form a first suspension and/or aryldihalophosphine is added to a second solvent at ambient temperature to form a second suspension, the first suspension and the second suspension may be combined at ambient temperature to form a combined solution, and the combined solution may be adjusted to the reaction temperature.
  • the temperature of any of the solvents or suspensions disclosed herein may be adjusted to the reaction temperature by any suitable mechanism for adjusting the temperature of solutions or suspensions.
  • the solution comprising NaBH 4 , aryldihalophosphine, and a solvent comprising at least 50 vol% glycol ethers is maintained at the reaction temperature for a duration of time.
  • the duration of time is from 0.05 hours to 12.00 hours, such as from 0.10 hours to 12.00 hours, from 0.50 hours to 12.00 hours, from 1.00 hours to 12.00 hours, from 1.50 hours to 12.00 hours, from 2.00 hours to 12.00 hours, from 2.50 hours to 12.00 hours, from 3.00 hours to 12.00 hours, from 3.50 hours to 12.00 hours, from 4.00 hours to 12.00 hours, from 4.50 hours to 12.00 hours, from 5.00 hours to 12.00 hours, from 5.50 hours to 12.00 hours, from 6.00 hours to 12.00 hours, from 6.50 hours to 12.00 hours, from 6.50 hours to 12.00 hours, from 7.00 hours to 12.00 hours, from 7.50 hours to 12.00 hours, from 8.00 hours to 12.00 hours, from 8.50 hours to 12.00 hours, from 9.00 hours to 12.00 hours, from 9.50 hours to 12.00 hours, from 10.00 hours to 12.00 hours, from 10.50 hours to 12.00 hours, from 11.00 hours to 12.00 hours, or from 11.50 hours to 12.00 hours.
  • the duration of time is from 0.05 hours to 11.50 hours, such as from 0.05 hours to 11.00 hours, from 0.05 hours to 10.50 hours, from 0.05 hours to 10.00 hours, from 0.05 hours to 9.50 hours, from 0.05 hours to 9.00 hours, from 0.05 hours to 8.50 hours, from 0.05 hours to 8.00 hours, from 0.05 hours to 7.50 hours, from 0.05 hours to 7.00 hours, from 0.05 hours to 6.50 hours, from 0.05 hours to 11.50 hours, such as from 0.05 hours to 11.00 hours, from 0.05 hours to 10.50 hours, from 0.05 hours to 10.00 hours, from 0.05 hours to 9.50 hours, from 0.05 hours to 9.00 hours, from 0.05 hours to 8.50 hours, from 0.05 hours to 8.00 hours, from 0.05 hours to 7.50 hours, from 0.05 hours to 7.00 hours, from 0.05 hours to 6.50 hours, from 0.05 hours to 11.50 hours, such as from 0.05 hours to 11.00 hours, from 0.05 hours to 10.50 hours, from 0.05 hours to 10.00 hours, from 0.05 hours to 9.50 hours,
  • the duration of time is from 0.10 hours to 11.50 hours, such as from 0.50 hours to 11.00 hours, from 1.00 hours to 10.50 hours, from 1.50 hours to 10.00 hours, from 2.00 hours to 9.50 hours, from 2.50 hours to 9.00 hours, from 3.00 hours to 8.50 hours, from
  • reaction time is from 0.10 hours to 2.00 hours, such as from 0.50 hours to 1.50 hours, or 1.00 hour.
  • Methods for preparing phosphine-borane complexes from aryldihalophosphine comprise mixing NaBH 4 , a solvent comprising at least 50 vol% DME, and aryldichlorophosphine to obtain a solution; and maintaining the solution at a reaction temperature for a duration of time to obtain the phosphine-borane complexes.
  • the aryldichlorophosphine is mono-aryldichlorophosphine.
  • the solvent further comprises THF.
  • Methods for preparing phosphine-borane complexes from aryldihalophosphine comprise obtaining a solution comprising NaBH 4 suspended in a solvent comprising at least 50 vol% DME; adjusting a temperature of the solution to a reaction temperature; obtaining a combined solution by combining the solution with a second solution, wherein the second solution comprises aryldichlorophosphine and a second solvent; and maintaining the combined solution at the reaction temperature for a duration of time to obtain the phosphine-borane complexes.
  • the aryldichlorophosphine is mono- aryldichlorophosphine.
  • the solvent further comprises THF.
  • the second solvent may, in embodiments, comprise THF.
  • the conversion of the aryldihalophosphine in a solution comprising NaBH 4 and at least 50 vol% glycol ethers to arylphosphine-borane complexes is at least 90%, such as at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.
  • the conversion of the aryldihalophosphine in a solution comprising NaBH 4 and at least 50 vol% glycol ethers to arylphosphine-borane complexes is 100%.
  • the mixture was maintained at 2 °C for a duration of half an hour (0.50 hours).
  • 20 ml hexane was added to the flask and more solid precipitated out.
  • the white slurry was filtered and the solid was washed by an additional 20 ml of hexane.
  • the filtrate turned hazy, which was then filtered again to remove the solid.
  • the solvent was removed and led to a white solid, which was further dried in the vacuum oven at 40 °C.
  • the yield of the 2,4-dimethoxyphenylphosphine)-borane complex was 1.62 g (82%).
  • EXAMPLE 2 [0034] In a three-neck flask, 16 ml DME as was used in Example 1 was loaded and cooled to 0 °C and sparged with N 2 for 0.50 hours. Subsequently, 0.5 g of NaBH 4 solid was loaded into the flask. Then, 0.9 g (5 mmol) dichlorophenylphosphine as obtained from a commercial supplier was diluted in 4 ml N 2 sparged DME was slowly added to the flask at a temperature range from 1 °C to 7 °C. The mixture was maintained at 2 °C for one hour.
  • THF to DME ratios of 3:1 and above do not provide an observable yield of 2, 4-dimethoxyphenylphosphine complex, but the yield of 2,4- dimethoxyphenylphosphine complex increases significantly from a THF to DME ratio of 3:1 to a THF to DME ratio of 1 : 1.
  • NaBH 4 in an appropriate amount based on desired molar ratio to 2,4- (dimethoxyphenyl)dichlorophosphine (ArPCl 2 ) as shown in Table 3 below was added to a three- neck round bottom flask equipped with a condenser, thermometer and a septa. This flask was evacuated under vacuum and refilled with N 2 three times before DME (2.27 g) was added via syringe. 5.62 g of a 17.0 weight percent (wt%) ArPCl 2 stock solution (with ArPCl 2 0.962 g, 4.09 mmol) was added to the vial via syringe over a period of 0.5 hour and left stirring at room temperature overnight. Table 3 shows the results of this test.
  • ArPCl 2 2,4- (dimethoxyphenyl)dichlorophosphine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

A method for preparing phosphine-borane complexes from aryldihalophosphine includes mixing sodium borohydride, a solvent having at least 50 vol% glycol ethers, and the aryldihalophosphine to obtain a solution. The solution is maintained at a reaction temperature for a duration of time to obtain the phosphine-borane complexes. The solvent may include 1,2-dimethoxyethane and tetrahydrofuran. A ratio of tetrahydrofuran to 1,2-dimethoxyethane in the solvent may be from 0.1:1.0 to 2.5:1.0.

Description

METHODS FOR PREPARING ARYLPHOSPHINE-BORANE COMPLEXES
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. Application Serial No. 62/734,500 filed on September 21, 2018, the entire disclosure of which is hereby incorporated by reference.
BACKGROUND
Field
[0002] The present specification generally relates to methods for preparing borane complexes from aryldihalophosphines. In particular, the present specification is directed to methods for preparing borane complexes from aryldihalophosphines with a solution comprising sodium borohydride.
Technical Background
[0003] Arylphosphines have potential uses as raw materials to commercial ligands in transition metal catalysis. However, phosphines are prone to oxidation and/or combustion, which make them dangerous to transport and handle. Accordingly, intermediary complexes of arylphosphines are formed that are less dangerous to transport and handle. The intermediary complexes can either be used in place of arylphosphines, or the intermediary complexes can be converted back to arylphosphines when they have safely been transported and/or handled. Intermediary complexes of arylphosphines that have been particularly useful are borane complexes of arylphosphines.
[0004] Unfortunately, known methods for preparing arylphosphines-borane complexes typically require borane reagents for production of arylphosphine-borane complexes.
SUMMARY
[0005] According to embodiments, methods for preparing phosphine-borane complexes from aryldihalophosphine comprise: mixing sodium borohydride (NaBH4), a solvent comprising at least 50 volume percent (vol%) glycol ethers, and the aryldihalophosphine to obtain a solution; and maintaining the solution at a reaction temperature for a duration of time to obtain the phosphine-borane complexes. [0006] According to embodiments, the glycol ethers comprises l,2-dimethoxyethane, and in some embodiments, the solvent further comprises tetrahydrofuran. In further embodiments, a ratio of tetrahydrofuran to l,2-dimethoxyethane in the solvent comprising may be from 0.1: 1.0 to 2.5: 1.0. In some embodiments, a ratio of sodium borohydride to aryldihalophosphine is from 1.1:1.0 to 2.5:l.O.
[0007] Additional features and advantages will be set forth in the detailed description which follows, and in part will be readily apparent to those skilled in the art from that description or recognized by practicing the embodiments described herein, including the detailed description which follows and the claims.
[0008] It is to be understood that both the foregoing general description and the following detailed description describe various embodiments and are intended to provide an overview or framework for understanding the nature and character of the claimed subject matter. The accompanying drawings are included to provide a further understanding of the various embodiments, and are incorporated into and constitute a part of this specification.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] FIG. 1 is a 1H NMR spectrum and peak assignments for a 2,4- dimethoxyphenylphosphine-borane complex according to embodiments disclosed and described herein;
[0010] FIG. 2 is a 13C NMR spectrum and peak assignments for a 2,4- dimethoxyphenylphosphine-borane complex according to embodiments disclosed and described herein;
[0011] FIG. 3 is a 31 P NMR spectrum for 2,4-dimethoxyphenylphosphine-borane complex (upper spectrum), 2,4-dimethoxyphenyl-P,P-dichlorophosphine (lower spectrum), and 2,4- dimethoxyphenylpho spine (inset) according to embodiments disclosed and described herein; and
[0012] FIG. 4 is a 31 P NMR spectrum for phenylphosphine-borane complex according to the embodiments disclosed and described herein.
DETAILED DESCRIPTION
[0013] Common abbreviations are listed below: [0014] BH THF: borane tetrahydrofuran complex; BH3-SMe2: borane dimethyl sulfide; NaBH4: sodium borohydride; DME: l,2-dimethoxyethane; THF: tetrahydrofuran; CDC13; deuterated chloroform; ZnCl2: zinc chloride; s: seconds; ppm: parts per million; Hz: hertz; psec: microseconds; mm: millimeter; g: gram; mmol: millimolar; and mL: milliliter.
[0015] Aryl phosphine borane complexes are generally prepared in two steps: (1) reduction of an aryldichlorophosphine to a phosphine; and (2) subsequent reaction with a borane source such as borane tetrahydrofuran complex (BH3 THF) or borane dimethyl sulfide (BH3 SMe2). However, these preparations are challenging for scale-up because of the instability of the BH3 THF complex and the release of SMe2 from the BH3-SMe2 complex. Another preparation route that has been considered and is used to form borane complexes with some phosphines include using sodium borohydride (NaBH4). However, the use of NaBH4 to reduce aryldihalophosphines is complicated by: (1) the insolubility of NaBH4 in most aprotic solvents; and (2) the susceptibility of solvolysis of aryldihalophosphines by protic solvents. Additionally, common uses of NaBH4 are able to utilize all of the reducing equivalents of BH4 , but it is has been found herein that for aryldihalophosphines, that two molar equivalents of BH4 are required to fully reduce the aryldihalophosphine, suggesting that only one hydride equivalent is used for each BH4 molecule. Taking these considerations into account, methods for preparing phosphine-borane complexes from aryldihalophosphine according to embodiments disclosed and described herein comprise: mixing sodium borohydride (NaBH4), a solvent comprising at least 50 vol% glycol ethers, and the aryldihalophosphine to obtain a solution; and maintaining the solution at a reaction temperature for a duration of time to obtain the phosphine-borane complexes.
[0016] As disclosed above, methods for preparing phosphine-borane complexes from aryldihalophosphine according to embodiments comprises mixing NaBH4 and the aryldihalophosphine in a solvent comprising 50 vol% glycol ethers. The NaBH4 used in methods for preparing phosphine-borane complexes is not limited and can be commercially available NaBH4. In some embodiments, the NaBH4 is powdered NaBH4 with a purity greater than 98%, such as greater than 99%. The aryldihalophosphine that is mixed with NaBH4 to form an arylphosphine-borane complex may be, in embodiments, an aryldichlorophosphine, such as, for example, an aryldichlorophosphine selected from the group consisting of dichloro(2,4- dimethoxyphenyl)phosphine, dichloro(2-methoxyphenyl)phosphine, and dichlorophenylphosphine. In some embodiments, the aryldihalophosphine may be a mono-aryldihalophosphine, such as, for example, mono-aryldichlorophosphine. The solvent used to prepare phosphine-borane complexes from aryldihalophosphine is, in embodiments, of particular importance. For instance, THF is a solvent that is commonly used to form phosphine- borane complexes. Traditionally, THF is used as the sole solvent for preparing phosphine- borane complexes. However, it was found that a solvent comprising THF alone will not produce a phosphine-borane complex with NaBH4 and aryldihalophosphine, such as, for example, aryldichlorophosphine. The solution to this issue is not readily ascertainable. For example, Lam, Hubert et al., Mild Reduction of Chlorophosphine Boranes to Secondary Phosphine Boranes, 44 Tetrahedron Letters, 5213-5216 (2003) discloses that a preformed chlorophosphine-borane complex, generated by mixing the chloropho spine and BH3»THF, produced a phosphine-borane complex by mixing NaBH4 and diary lmonohalophosphine-borane complex in a solvent that only comprises THF ( i.e solvent is 100 vol% THF). However, as disclosed above, NaBH4 and aryldihalophosphine will not form a phosphine-borane complex in a solvent that only comprises THF. This indicates that the chemistry involved in forming the phosphine-borane complexes with NaBH4 and phosphines is complex and highly dependent on the structure of the phosphine and the composition of the solvent. Embodiments of methods for preparing phosphine-borane complexes from aryldihalophosphine disclosed and described herein address this issue, and provide methods for forming phosphine-borane complexes from aryldihalophosphine and NaBH4.
[0017] According to embodiments, a phosphine-borane complex is prepared by mixing NaBH4 and aryldihalophosphine in a solvent. According to some embodiments, a desired phosphine-borane complex may be formed by mixing NaBH4 and aryldihalophosphine at an appropriate ratio. Without being bound to any particular theory, if not enough NaBH4 is added to the solvent, phosphine-borane complexes will not be formed. However, if too much NaBH4 is added to the solvent, undesired byproducts may be formed, and additional NaBH4 must be separated from the product. According to some embodiments, a ratio of NaBH4 to aryldichlorophosphine is from 1.1: 1.0 to 2.5: 1.0, such as from 1.2: 1.0 to 2.5: 1.0, from 1.3: 1.0 to 2.5: 1.0, from 1.4: 1.0 to 2.5: 1.0, from 1.5: 1.0 to 2.5: 1.0, from 1.6: 1.0 to 2.5: 1.0, from 1.7: 1.0 to 2.5:1.0, from 1.8:1.0 to 2.5:1.0, from 1.9:1.0 to 2.5:1.0, from 2.0:1.0 to 2.5:1.0, from 2.1:1.0 to 2.5: 1.0, from 2.2: 1.0 to 2.5: 1.0, from 2.3: 1.0 to 2.5: 1.0, or from 2.4: 1.0 to 2.5: 1.0. In embodiments a ratio of NaBH4 to aryldichlorophosphine is from 1.1: 1.0 to 2.4: 1.0, such as from 1.1:1.0 to 2.3:1.0, from 1.1:1.0 to 2.2:1.0, from 1.1:1.0 to 2.1:1.0, from 1.1:1.0 to 2.0:1.0, from 1.1:1.0 to 1.9:1.0, from 1.1:1.0 to 1.8:1.0, from 1.1:1.0 to 1.7:1.0, from 1.1:1.0 to 1.6:1.0, from 1.1:1.0 to 1.5:1.0, from 1.1:1.0 to 1.4:1.0, from 1.1:1.0 to 1.3:1.0, or from 1.1:1.0 to 1.2:1.0. In embodiments, a ratio of NaBH4 to aryldichlorophosphine is from 1.2: 1.0 to 2.4: 1.0, such as from 1.3: 1.0 to 2.3: 1.0, from 1.4: 1.0 to 2.2: 1.0, from 1.5: 1.0 to 2.1:1.0, from 1.6: 1.0 to 2.0: 1.0, or from 1.7: 1.0 to 1.9: 1.0. In embodiments, a ratio of NaBH4 to aryldichlorophosphine is from 1.5:1.0 to 2.2:1.0, such as from 1.6:1.0 to 2.1:1.0, from 1.7:1.0 to 2.0:1.0, or from 1.8:1.0 to 1.9:1.0.
[0018] Methods for preparing phosphine-borane complexes from aryldihalophosphine according to embodiments disclosed and described herein comprises mixing NaBH4 and aryldihalophosphine in a solvent comprising at least 50 vol% glycol ethers, such as at least 55 vol% glycol ethers, at least 60 vol% glycol ethers, at least 65 vol% glycol ethers, at least 70 vol% glycol ethers, at least 75 vol% glycol ethers, at least 80 vol% glycol ethers, at least 85 vol% glycol ethers, at least 90 vol% glycol ethers, or at least 95 vol% glycol ethers. According to some embodiments, the glycol ethers in the solvent may comprise 1,2- dimethoxyethane (DME), triglyme, diglyme, or mixtures thereof. In some embodiments, the glycol ethers in the solvent comprise DME. Accordingly, in some embodiments, the solvent in which NaBH4 and aryldihalophosphine is mixed may comprise at least 50 vol% DME, such as at least 55 vol% DME, at least 60 vol% DME, at least 65 vol% DME, at least 70 vol% DME, at least 75 vol% DME, at least 80 vol% DME, at least 85 vol% DME, at least 90 vol% DME, or at least 95 vol% DME.
[0019] As is apparent from the disclosure above, the solvent in which NaBH4 and aryldihalophosphine are mixed may, in embodiments, comprise components other than glycol ethers. According to some embodiments, the solvent in which NaBH4 and aryldihalophosphine are mixed may comprise tetrahydrofuran (THF), toluene, or mixtures thereof. In embodiments, the solvent may comprise from 5 vol% to 50 vol% THF, such as from 10 vol% to 50 vol% THF, from 15 vol% to 50 vol% THF, from 20 vol% to 50 vol% THF, from 25 vol% to 50 vol% THF, from 30 vol% to 50 vol% THF, from 35 vol% to 50 vol% THF, from 40 vol% to 50 vol% THF, or from 45 vol% to 50 vol% THF. In some embodiments, the solvent may comprise from 5 vol% to 45 vol% THF, such as from 5 vol% to 40 vol% THF, from 5 vol% to 35 vol% THF, from 5 vol% to 30 vol% THF, from 5 vol% to 25 vol% THF, from 5 vol% to 20 vol% THF, from 5 vol% to 15 vol% THF, or from 5 vol% to 10 vol% THF. In embodiments, the solvent may comprise from 10 vol% to 45 vol% THF, such as from 15 vol% to 40 vol% THF, from 20 vol% to 35 vol% THF, or from 25 vol% to 30 vol% THF.
[0020] In one or more embodiments, the solvent in which NaBH4 and aryldihalophosphine are mixed may comprise a mixture of DME and THF. In such embodiments, the solvent in which NaBH4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.1: 1.0 to 2.5: 1.0, such as from 0.2: 1.0 to 2.5: 1.0, from 0.3: 1.0 to 2.5: 1.0, from 0.4: 1.0 to 2.5: 1.0, from 0.5:1.0 to 2.5:1.0, from 0.6:1.0 to 2.5:1.0, from 0.7:1.0 to 2.5:1.0, from 0.8:1.0 to 2.5:1.0, from
0.9: 1.0 to 2.5: 1.0, from 1.0: 1.0 to 2.5: 1.0, from 1.1: 1.0 to 2.5: 1.0, from 1.2: 1.0 to 2.5: 1.0, from
1.3: 1.0 to 2.5: 1.0, from 1.4: 1.0 to 2.5: 1.0, from 1.5: 1.0 to 2.5: 1.0, from 1.6: 1.0 to 2.5: 1.0, from
1.7:1.0 to 2.5:1.0, from 1.8:1.0 to 2.5:1.0, from 1.9:1.0 to 2.5:1.0, from 2.0:1.0 to 2.5:1.0, from
2.1:1.0 to 2.5: 1.0, from 2.2: 1.0 to 2.5: 1.0, from 2.3: 1.0 to 2.5: 1.0, or from 2.4: 1.0 to 2.5: 1.0. In some embodiments, the solvent in which NaBH4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.1: 1.0 to 2.4: 1.0, such as from 0.1: 1.0 to 2.3: 1.0, from 0.1: 1.0 to 2.2: 1.0, from 0.1: 1.0 to 2.2: 1.0, from 0.1: 1.0 to 2.1:1.0, from 0.1: 1.0 to 2.0: 1.0, from 0.1: 1.0 to
1.9:1.0, from 0.1:1.0 to 1.8:1.0, from 0.1:1.0 to 1.7:1.0, from 0.1:1.0 to 1.6:1.0, from 0.1:1.0 to
1.5:1.0, from 0.1:1.0 to 1.4:1.0, from 0.1:1.0 to 1.3:1.0, from 0.1:1.0 to 1.2:1.0, from 0.1:1.0 to
1.1:1.0, from 0.1:1.0 to 1.0:1.0, from 0.1:1.0 to 0.9:1.0, from 0.1:1.0 to 0.8:1.0, from 0.1:1.0 to
0.7:1.0, from 0.1:1.0 to 0.6:1.0, from 0.1:1.0 to 0.5:1.0, from 0.1:1.0 to 0.4:1.0, from 0.1:1.0 to
0.3: 1.0, or from 0.1: 1.0 to 0.2: 1.0. In one or more embodiments, the solvent in which NaBH4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.2: 1.0 to 2.4: 1.0, such as from 0.3: 1.0 to 2.3: 1.0, from 0.4: 1.0 to 2.2: 1.0, from 0.5: 1.0 to 2.1:1.0, from 0.6: 1.0 to
2.0:1.0, from 0.7:1.0 to 1.9:1.0, from 0.8:1.0 to 1.8:1.0, from 0.9:1.0 to 1.7:1.0, from 1.0:1.0 to
1.6: 1.0, from 1.1: 1.0 to 1.5: 1.0, or from 1.2: 1.0 to 1.4: 1.0. In embodiments, the solvent in which NaBH4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.1: 1.0 to 1.0:1.0, such as from 0.2:1.0 to 0.9:1.0, from 0.3:1.0 to 0.8:1.0, from 0.4:l.0 to 0.7:1.0, or from 0.5:1.0 to 0.7:1.0.
[0021] According to embodiments, NaBH4 and aryldihalophosphine may be mixed by adding each as a dry component to a solvent that comprises at least 50 vol% glycol ethers. In some embodiments, NaBH4 may be added to a first solvent to form a first suspension, and aryldihalophosphine may be added to a second solvent to form a second suspension. In such embodiments, the first suspension and the second suspension are combined, which results in mixing the NaBH4 and aryldihalophosphine. In various embodiments, the first solvent and the second solvent may be the same or different. In embodiments where the first solvent and the second solvent are the same, each of the first solvent and the second solvent may comprise at least 50 vol% glycol ethers so that when the first suspension and the second suspension are combined, the combined solvent comprises at least 50 vol% glycol ethers. In embodiments where the first solvent and the second solvent are different, the composition of the first solvent and the composition of the second solvent should be formulated such that when the first suspension and the second suspension are combined, the combined solvent comprises at least 50 vol% glycol ethers. It should be understood that a skilled artisan is capable of formulating the first solvent and the second solvent so that when the first suspension and the second suspension are combined, the combined solvent comprises at least 50 vol% glycol ethers. Thus, in one or more embodiments, at least one of the first solvent and/or the second solvent comprises at least 50 vol% glycol ethers. In some embodiments, at least one of the first solvent and/or the second solvent may comprise THF. In embodiments, where one of the first solvent and/or the second solvent comprises THF and one of the first solvent or the second solvent comprises DME, the first solvent and the second solvent may be formulated to yield the THF to DME ratios disclosed herein.
[0022] As disclosed above, embodiments of methods for preparing phosphine borane complexes disclosed and described herein comprise mixing NaBH4 and aryldihalophosphine in a solvent comprising at least 50 vol% glycol ethers to obtain a solution, and maintaining the solution at a reaction temperature. In embodiments, the reaction temperature may be from 0 °C to 60 °C, such as from 5 °C to 60 °C, from 10 °C to 60 °C, from 15 °C to 60 °C, from 20 °C to 60 °C, from 25 °C to 60 °C, from 30 °C to 60 °C, from 35 °C to 60 °C, from 40 °C to 60 °C, from 45 °C to 60 °C, from 50 °C to 60 °C, or from 55 °C to 60 °C. In some embodiments, the reaction temperature may be from 0 °C to 55 °C, such as from 0 °C to 50 °C, from 0 °C to 45 °C, from 0 °C to 40 °C, from 0 °C to 35 °C, from 0 °C to 30 °C, from 0 °C to 25 °C, from 0 °C to 20 °C, from 0 °C to 15 °C, from 0 °C to 10 °C, or from 0 °C to 5 °C. In embodiments, the reaction temperature may be from 5 °C to 55 °C, such as from 10 °C to 50 °C, from 15 °C to 45 °C, from 20 °C to 40 °C, or from 20 °C to 35 °C.
[0023] In some embodiments, the solvent may be adjusted to the reaction temperature before NaBH4 and/or aryldihalophosphine is added to the solvent. In embodiments, NaBH4 and/or aryldihalophosphine may be added to the solvent at ambient temperature and the mixture of NaBH4, aryldihalophosphine, and solvent are adjusted to the reaction temperature. In embodiments, NaBH4 is added to a first solvent to form a first suspension and aryldihalophosphine is added to a second solvent to form a second suspension, the first solvent and/or the second solvent may be adjusted to the reaction temperature before the NaBH4 and/or aryldihalophosphine is added to the first solvent and/or second solvent, respectively. In some embodiments, NaBH4 is added to a first solvent at ambient temperature to form a first suspension and/or aryldihalophosphine is added to a second solvent at ambient temperature to form a second suspension, and the first suspension and/or the second suspension may be adjusted to the reaction temperature after the NaBH4 and/or aryldihalophosphine is added to the first solvent and/or second solvent, respectively. In some embodiments, NaBH4 is added to a first solvent at ambient temperature to form a first suspension and/or aryldihalophosphine is added to a second solvent at ambient temperature to form a second suspension, the first suspension and the second suspension may be combined at ambient temperature to form a combined solution, and the combined solution may be adjusted to the reaction temperature. The temperature of any of the solvents or suspensions disclosed herein may be adjusted to the reaction temperature by any suitable mechanism for adjusting the temperature of solutions or suspensions.
[0024] As disclosed herein, according to embodiments for preparing phosphine-borane complexes from aryldihalophosphine, the solution comprising NaBH4, aryldihalophosphine, and a solvent comprising at least 50 vol% glycol ethers is maintained at the reaction temperature for a duration of time. In embodiments, the duration of time is from 0.05 hours to 12.00 hours, such as from 0.10 hours to 12.00 hours, from 0.50 hours to 12.00 hours, from 1.00 hours to 12.00 hours, from 1.50 hours to 12.00 hours, from 2.00 hours to 12.00 hours, from 2.50 hours to 12.00 hours, from 3.00 hours to 12.00 hours, from 3.50 hours to 12.00 hours, from 4.00 hours to 12.00 hours, from 4.50 hours to 12.00 hours, from 5.00 hours to 12.00 hours, from 5.50 hours to 12.00 hours, from 6.00 hours to 12.00 hours, from 6.50 hours to 12.00 hours, from 6.50 hours to 12.00 hours, from 7.00 hours to 12.00 hours, from 7.50 hours to 12.00 hours, from 8.00 hours to 12.00 hours, from 8.50 hours to 12.00 hours, from 9.00 hours to 12.00 hours, from 9.50 hours to 12.00 hours, from 10.00 hours to 12.00 hours, from 10.50 hours to 12.00 hours, from 11.00 hours to 12.00 hours, or from 11.50 hours to 12.00 hours. In some embodiments, the duration of time is from 0.05 hours to 11.50 hours, such as from 0.05 hours to 11.00 hours, from 0.05 hours to 10.50 hours, from 0.05 hours to 10.00 hours, from 0.05 hours to 9.50 hours, from 0.05 hours to 9.00 hours, from 0.05 hours to 8.50 hours, from 0.05 hours to 8.00 hours, from 0.05 hours to 7.50 hours, from 0.05 hours to 7.00 hours, from 0.05 hours to 6.50 hours, from 0.05 hours to
6.00 hours, from 0.05 hours to 5.50 hours, from 0.05 hours to 5.00 hours, from 0.05 hours to
4.50 hours, from 0.05 hours to 4.00 hours, from 0.05 hours to 3.50 hours, from 0.05 hours to
3.00 hours, from 0.05 hours to 2.50 hours, from 0.05 hours to 2.00 hours, from 0.05 hours to
1.50 hours, from 0.05 hours to 1.00 hours, from 0.05 hours to 0.50 hours, or from 0.05 hours to 0.10 hours. In embodiments, the duration of time is from 0.10 hours to 11.50 hours, such as from 0.50 hours to 11.00 hours, from 1.00 hours to 10.50 hours, from 1.50 hours to 10.00 hours, from 2.00 hours to 9.50 hours, from 2.50 hours to 9.00 hours, from 3.00 hours to 8.50 hours, from
3.50 hours to 8.00 hours, from 4.00 hours to 7.50 hours, from 4.50 hours to 7.00 hours, from 5.00 hours to 6.50 hours, or from 5.50 hours to 6.00 hours. In some embodiments, the reaction time is from 0.10 hours to 2.00 hours, such as from 0.50 hours to 1.50 hours, or 1.00 hour.
[0025] Methods for preparing phosphine-borane complexes from aryldihalophosphine, according to embodiments, comprise mixing NaBH4, a solvent comprising at least 50 vol% DME, and aryldichlorophosphine to obtain a solution; and maintaining the solution at a reaction temperature for a duration of time to obtain the phosphine-borane complexes. In some embodiments, the aryldichlorophosphine is mono-aryldichlorophosphine. In one or more embodiments, the solvent further comprises THF.
[0026] Methods for preparing phosphine-borane complexes from aryldihalophosphine, according to embodiments, comprise obtaining a solution comprising NaBH4 suspended in a solvent comprising at least 50 vol% DME; adjusting a temperature of the solution to a reaction temperature; obtaining a combined solution by combining the solution with a second solution, wherein the second solution comprises aryldichlorophosphine and a second solvent; and maintaining the combined solution at the reaction temperature for a duration of time to obtain the phosphine-borane complexes. In some embodiments, the aryldichlorophosphine is mono- aryldichlorophosphine. In one or more embodiments, the solvent further comprises THF. The second solvent may, in embodiments, comprise THF.
[0027] According to embodiments the conversion of the aryldihalophosphine in a solution comprising NaBH4 and at least 50 vol% glycol ethers to arylphosphine-borane complexes is at least 90%, such as at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In some embodiments, the conversion of the aryldihalophosphine in a solution comprising NaBH4 and at least 50 vol% glycol ethers to arylphosphine-borane complexes is 100%.
EXAMPLES
[0028] Embodiments will be further clarified by the following examples.
EXAMPLE 1
[0029] Dichloro(2,4-dimethoxyphenylphosphine) was prepared using Friedel-Crafts reaction using anhydrous technical grade ZnCl2 as the catalyst, which was not further purified prior to the reduction reaction.
[0030] In a three-neck flask, 30 ml DME (>99% purity obtained from Sigma Aldrich) was loaded and cooled to 0 °C. One gram (g) of NaBH4 solid (>98% purity powder obtained from Sigma Aldrich) was loaded into the flask, and a small temperature increase of 2 °C was observed. Subsequently, 2.46 g (8.6 millimolar (mmol)) dichloro(2,4- dimethoxyphenylphosphine) (84% purity) diluted in 8 milliliter (mL) N2 sparged DME was slowly added to the flask at a temperature ranging from 2 °C to 6 °C. The mixture was maintained at 2 °C for a duration of half an hour (0.50 hours). Next, 20 ml hexane was added to the flask and more solid precipitated out. The white slurry was filtered and the solid was washed by an additional 20 ml of hexane. The filtrate turned hazy, which was then filtered again to remove the solid. The solvent was removed and led to a white solid, which was further dried in the vacuum oven at 40 °C. The yield of the 2,4-dimethoxyphenylphosphine)-borane complex was 1.62 g (82%).
[0031] The 2, 4-dimethoxyphenylphosphine-borane complex was dissolved in deuterated chloroform (CDC13) in a 5 mm NMR tube. 13 C NMR experiment was performed on a Bruker Avance 400 NMR spectrometer equipped with a 10 mm C/H DUAL cryoprobe. Both inverse- gated quantitative C NMR and DEPT-135 experiments were performed without sample spinning. Data were processed using MNOVA software with a 1 Hz lining broadening. The following is the setup of acquisition parameters:
Temperature: 25 °C
Solvent: CDCI3
Acquisition: 1024 scans Spectrum reference: 77.3 ppm for solvent
Relaxation delay: 30 s
Spectrum center: 100 ppm
90 ° pulse length: 11.0 / s
Spectral width: 250 ppm
[0032] Standard quantitative 1H NMR experiments were performed without sample spinning on the same instrument. Data were processed using MNOVA software with a 0.5 Hz lining broadening. The following is the setup of acquisition parameters:
Temperature: 25 °C
Solvent: CDCl3
Acquisition: 16 scans
Spectrum reference: 7.27 ppm for solvent
Relaxation delay: 30 s
Spectrum center: 5 ppm
90 ° pulse length: 17.2 /is
Spectral width: 20 ppm
[0033] 1H NMR spectrum is shown in FIG. 1. By the peak intensity ratio, every aromatic ring has three BH3 protons associated with it. The three bond H-B-P-H vicinal coupling was clearly observed (quartets at 5.85 and 4.90 ppm), providing direct evidence of 2, 4- dimethoxyphenylphosphine-borane complex. Purity of the product was demonstrated by C NMR spectrum in FIG. 2, where the unassigned peaks (labeled with asterisks) are from the unreacted dimethoxybenzene carried over from the first step reaction. The conversion of dichloro(2, 4-dimethoxy)phenylphosphine to 2, 4-dimethoxyphenylphosphine-borane complex is almost complete, indicating by negligible byproduct peaks. In FIG. 3, the starting dichloro(2,4-dimethoxphenyl)phosphine has a peak at 166 ppm. After forming the phenylphosphine-borane complex, the peak is shifted to -43 ppm. As a reference for comparison, the phenylphosphine without complex has a chemical shift at -146 ppm, which is shown in the inset of FIG. 3.
EXAMPLE 2 [0034] In a three-neck flask, 16 ml DME as was used in Example 1 was loaded and cooled to 0 °C and sparged with N2 for 0.50 hours. Subsequently, 0.5 g of NaBH4 solid was loaded into the flask. Then, 0.9 g (5 mmol) dichlorophenylphosphine as obtained from a commercial supplier was diluted in 4 ml N2 sparged DME was slowly added to the flask at a temperature range from 1 °C to 7 °C. The mixture was maintained at 2 °C for one hour. An NMR sample obtained as outlined in Example 1 indicated the full conversion of dichloro((phenyl)phosphine to phenylphosphine-borane complex. This is evident form the single P peak on NMR graph shown in FIG. 4 at -49 ppm. The starting material, dichloro(phenyl)phosphine, P NMR resonance is observed at 163 ppm, and the decomplexed phenylphosphine 31P NMR resonance is observed at -122 ppm.
EXAMPLE 3
[0035] In a three-neck flask, 15 ml of DME was loaded. Subsequently, 0.5 g of NaBH4 solid was loaded into the flask. A solution of 1.16 g (4.3 mmol) dichloro(2,4- dimethoxyphenylphosphine) (89% purity) obtained as in Example 1 in 4 ml N2 sparged DME was prepared. The dichloro(2,4-dimethoxyphenylphosphine) solution was added into mixtures of DME and NaBH4. The NaBH4 mixtures were set at 0 °C, 30 °C, and 60 °C. After the addition of dichloro(2, 4-dimethoxyphenylphosphine) was complete, the reactions were kept at the respective temperatures for 4 hours. The resulting solutions were quenched with water, and analyzed by P NMR using tri(ortho-tolyl)phosphine as an internal standard. Table 1 below shows the results of this example and the effect of temperature on the preparation of phosphine - borane complexes.
[0036] Table 1
[0037] As can be seen from Table 1, there is a sharp increase in percentage yield as the reaction temperature increases from 0 °C to 30 °C, but the increase in percentage yield is not as pronounced as the reaction temperature increases from 30 °C to 60 °C. This indicates that temperatures above 60 °C do not provide significant improvements in percentage yield. The range of yields observed at 0 °C were measured across three independent reactions.
EXAMPLE 4
[0038] In a three-neck flask, a total of 15 ml THF and DME was loaded at the THF to DME ratios shown in Table 2 below. Subsequently, 0.5 g of NaBH4 solid was loaded into the flask. Then, 1.16 g (4.3 mmol) dichloro(2, 4-dimethoxyphenylphosphine) (89% purity) as obtained in Example 1 and diluted in 4 ml N2 sparged THF was slowly added to the flask at 23 °C. The reactions were sampled at 25 minutes and 16 hours after this THF addition was complete, and the samples were analyzed by P NMR. Table 2 shows the effect of the THF to DME ratio on percentage yield.
[0039] Table 2
[0040] As shown in Table 2, THF to DME ratios of 3:1 and above do not provide an observable yield of 2, 4-dimethoxyphenylphosphine complex, but the yield of 2,4- dimethoxyphenylphosphine complex increases significantly from a THF to DME ratio of 3:1 to a THF to DME ratio of 1 : 1.
EXAMPLE 5
[0041] NaBH4 in an appropriate amount based on desired molar ratio to 2,4- (dimethoxyphenyl)dichlorophosphine (ArPCl2) as shown in Table 3 below was added to a three- neck round bottom flask equipped with a condenser, thermometer and a septa. This flask was evacuated under vacuum and refilled with N2 three times before DME (2.27 g) was added via syringe. 5.62 g of a 17.0 weight percent (wt%) ArPCl2 stock solution (with ArPCl20.962 g, 4.09 mmol) was added to the vial via syringe over a period of 0.5 hour and left stirring at room temperature overnight. Table 3 shows the results of this test.
[0042] Table 3
a GC yield with dodecane as internal standard; bNMR yield
[0043] As shown in Table 3, the percentage yield of phosphine-borane complexes increases sharply as the ratio of NaBH4 to ArPCl2 increases from 1:1 to 2.2:1
[0044] It will be apparent to those skilled in the art that various modifications and variations can be made to the embodiments described herein without departing from the spirit and scope of the claimed subject matter. Thus it is intended that the specification cover the modifications and variations of the various embodiments described herein provided such modification and variations come within the scope of the appended claims and their equivalents.

Claims

1. A method for preparing phosphine -borane complexes from aryldihalophosphine comprising:
mixing sodium borohydride, a solvent comprising at least 50 vol% glycol ethers, and the aryldihalophosphine to obtain a solution; and
maintaining the solution at a reaction temperature for a duration of time to obtain the phosphine-borane complexes.
2. The method of claim 1, wherein the solution is adjusted to the reaction temperature.
3. The method of claim 1, wherein mixing the sodium borohydride, the solvent comprising at least 50 vol% glycol ethers, and the aryldihalophosphine comprises adding the sodium borohydride and aryldihalophosphine to the solvent comprising at least 50 vol% glycol ethers, and
the solvent comprising at least 50 vol% glycol ethers is adjusted to the reaction temperature before adding the sodium borohydride and aryldihalophosphine to the solvent comprising at least 50 vol% glycol ethers.
4. The method of any one of claims 1 to 3, wherein the aryldihalophosphine is an aryldicholoropho sphine .
5. The method of any one of claims 1 to 4, wherein the aryldihalophosphine is a mono ary ldichloropho sphine .
6. The method of any one of claims 1 to 5, wherein the aryldihalophosphine is selected from the group consisting of dichloro(2,4-dimethoxyphenyl)phosphine, dichloro(2- methoxyphenyljphosphine, and dichlorophenylphosphine.
7. The method of any one of claims 1 to 6, wherein the glycol ethers is selected from the group consisting of l,2-dimethoxyethane, diglyme, triglyme, and mixtures thereof.
8. The method of any one of claims 1 to 7, wherein the glycol ethers comprises 1,2- dimethoxyethane.
9. The method of claim 8, wherein the solvent comprising at least 50 vol% glycol ethers further comprises tetrahydrofuran.
10. The method of claim 9, wherein a ratio of tetrahydrofuran to l,2-dimethoxyethane in the solvent comprising at least 50 vol% glycol ethers is from 0.1: 1.0 to 2.5: 1.0.
11. The method of any one of claims 9 and 10, wherein a ratio of tetrahydrofuran to 1,2- dimethoxyethane the solvent comprising at least 50 vol% glycol ethers is from 0.1: 1.0 to 1.0: 1.0.
12. The method of any one of claims 1 to 11, wherein a ratio of sodium borohydride to aryldihalophosphine is from 1.1: 1.0 to 2.5: 1.0.
13. The method of any one of claims 1 to 12, wherein wherein a ratio of sodium borohydride to aryldihalophosphine is from 1.5: 1.0 to 2.2: 1.0.
14. The method of any one of claims 1 to 13, wherein the reaction temperature is from 0 °C to 60 °C.
15. The method of any one of claims 1 to 14, wherein the duration of time is from 0.05 hours to 12.00 hours.
EP19779698.0A 2018-09-21 2019-09-18 Methods for preparing arylphosphine-borane complexes Active EP3853172B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862734500P 2018-09-21 2018-09-21
PCT/US2019/051662 WO2020061151A1 (en) 2018-09-21 2019-09-18 Methods for preparing arylphosphine-borane complexes

Publications (2)

Publication Number Publication Date
EP3853172A1 true EP3853172A1 (en) 2021-07-28
EP3853172B1 EP3853172B1 (en) 2023-07-05

Family

ID=68084992

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19779698.0A Active EP3853172B1 (en) 2018-09-21 2019-09-18 Methods for preparing arylphosphine-borane complexes

Country Status (7)

Country Link
US (1) US20210380613A1 (en)
EP (1) EP3853172B1 (en)
CN (1) CN113272247B (en)
CA (1) CA3113090A1 (en)
ES (1) ES2952375T3 (en)
SA (1) SA521421525B1 (en)
WO (1) WO2020061151A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2892873A (en) * 1957-04-22 1959-06-30 American Potash & Chem Corp Phosphinoborines
GB908106A (en) * 1959-08-27 1962-10-17 Ici Ltd Improvements in and relating to the production of organic compounds containing boronand phosphorus
US5399780A (en) * 1992-11-02 1995-03-21 Tosoh Akzo Corporation Method of producing triarylborane
US6048985A (en) * 1998-12-22 2000-04-11 Mine Safety Appliances Company Borane-tetrahydrofuran complex method of storing and reacting borane-tetrahydrofuran complex
RU2223277C1 (en) * 2002-11-21 2004-02-10 Общество с ограниченной ответственностью "Синор" Method for preparing alkyl(phenyl)phosphine- -borane complex
WO2005032712A1 (en) * 2003-10-01 2005-04-14 Dow Global Technologies Inc. Process for preparing cationic rhodium complexes
NZ573456A (en) * 2006-06-26 2010-08-27 Basf Se Borane ether complexes for organic reactions
CN103709195B (en) * 2013-12-11 2017-07-04 华东师范大学 Chiral sulfenamide class monophosphorus ligand, its full configuration preparation method and application

Also Published As

Publication number Publication date
CN113272247B (en) 2024-04-09
WO2020061151A1 (en) 2020-03-26
ES2952375T3 (en) 2023-10-31
EP3853172B1 (en) 2023-07-05
US20210380613A1 (en) 2021-12-09
BR112021005282A2 (en) 2021-06-15
SA521421525B1 (en) 2023-10-01
CA3113090A1 (en) 2020-03-26
CN113272247A (en) 2021-08-17

Similar Documents

Publication Publication Date Title
Brintzinger et al. Nature of so-called titanocene,(C10H10Ti) 2
Deacon et al. Organoamido-and Aryloxo-Lanthanoids. II. Preparation of Tris (2, 6-diphenylphenoxo)-lanthanoid (III) Complexes and the X-Ray Structures of Low-Coordinate [Yb (O-2, 6-Ph2C6H3) 3] Containing an Intramolecular Chelate Yb… π-Arene Interaction, and [Yb (O-2
Adhikary et al. Interaction of alkynes with palladium POCOP-pincer hydride complexes and its unexpected relation to palladium-catalyzed hydrogenation of alkynes
Camp et al. CS 2 activation at uranium (iii) siloxide ate complexes: the effect of a Lewis acidic site
Krieck et al. Straightforward synthesis of rubidium bis (trimethylsilyl) amide and complexes of the alkali metal bis (trimethylsilyl) amides with weakly coordinating 2, 2, 5, 5-tetramethyltetrahydrofuran
EP3853172A1 (en) Methods for preparing arylphosphine-borane complexes
Baudry et al. Pentadienyluranium borohydride complexes and their cyclopentadienyl analogues; crystal structures of (η-2, 4-Me2C5H5) U (BH4) 3 and (η-C5H5) U (BH4) 3
EP2459580B1 (en) Process for the preparation of palladium(i) tri-tert-butylphosphine bromide dimer
Mukherjee et al. Group 2 metal (Mg, Ca, Sr) silylamides supported by a cyclen-derived macrocyclic polyamine
Schmitz et al. Hydrostannylation of phosphaalkenes [1]
Brunner et al. The Reaction of As4Sn (n= 3, 4) and As2S3 with (C5Me4R) 2Co2 (CO) 2 (R= Me, Et): Fragmentation and Reassembling of Main‐Group Ligands by Organometallic Complexes
Peláez et al. Synthesis, Crystal Structures and Anticancer Activity of the New Chiral Mono‐and Dinuclear Palladium (II) Complexes derived from (S)‐(‐)‐(1‐phenylethylimino) benzylphenylketone
Guddorf et al. An intermolecular FLP System derived from an NHC-coordinated trisilacyclopropylidene
CN103889992B (en) All join rare earth triaryl coordination compound
Dorow et al. Coordination chemistry of alkali metal dimesityl-thio-and dimesityl-selenophosphinites [(L) 2 A-EPMes 2] 2 (A= Li, Na, K; E= S, Se; L= THF, THP) and [(18C6) K-SPMes 2]
Langer et al. Synthesis and crystal structures of bis (diphenylphosphanyl) methanides of lithium and calcium as well as of their borane adducts
Summerscales et al. Samarium (III) Pentalene Sandwich Compounds [Sm (η8-C8H4 {SiiPr3-1, 4} 2)(Cp*)] and [Sm (η8-C8H4 {SiiPr3-1, 4} 2)(η5-C8H5 {SiiPr3-1, 4} 2)] and a Mixed-Valence Hexasamarium Cluster Derived from Sm (II)-Based Solvent Activation
Yalpani et al. Bis (9‐borabicyclo [4.2. 1] nonanes)
BR112021005282B1 (en) METHOD FOR PREPARING PHOSPPHINE-BORANE COMPLEXES FROM ARILDI-HALOPHOSPHINE
Johnson et al. Preparation, X-ray structural analysis, and method of interconversion of two isomeric forms of [Os 6 (CO) 16 {P (OMe) 3} 2]
DE69920049T2 (en) PREPARATION OF ALKALIMETALL SUBSTITUTED BOROHYDRID REAGENTS
Wells et al. Synthesis and characterization of [(Me3SiCH2) 2GaP (SiMe3) 2] 2, an example of a gallium‐phosphorus dimer obtainable only through an indirect reaction pathway
SU549087A3 (en) Method for producing polyimine type aluminum compounds
Rivals et al. Syntheses and Structures of Trilithium Cyclotriphosphazenates Equipped with 2‐Halo‐aryl Substituents
Trace et al. In search of α-eliminations of carbon induced by sixteen electron iron: photolysis and thermolysis of derivatives of phenyl substituted cyclobutanes and cyclopropanes

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210408

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230208

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1584711

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019032223

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2952375

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20231031

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1584711

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231106

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231005

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231105

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231006

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019032223

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230918

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230918

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

26N No opposition filed

Effective date: 20240408

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20231005

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230918

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231005

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230930

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20190918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20190918

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250704

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250702

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20251016

Year of fee payment: 7